Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1649 1675
This examiner grants 54% of resolved cases
Kimberly Ballard is an examiner in Tech Center 1600, Art Unit 1649, with 656 resolved cases. The allowance rate is 53.7%, and the median days to allowance is 1214. These figures reflect a moderately rigorous prosecution process that often takes a lengthy period to reach a conclusion.
The interview lift is a high 49.0% over the 53.7% baseline, which significantly improves the chances of success. This suggests that Examiner Ballard is very open to resolving issues through direct communication and that interviews are an essential strategy. With 656 resolved cases and a 1214-day pendency, practitioners should prioritize interviews to bridge the gap and increase the likelihood of a patent grant. The 49.0% lift is a substantial benefit, indicating that verbal discussion can resolve rejections that persist in the written record. For applications on this docket, an interview is a key tactic for navigating the 1214-day timeline and improving the 53.7% baseline odds. The data clearly supports a strategy of early and frequent verbal engagement.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17711099 | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | Non-Final OA | Eli Lilly and Company |
| 17535059 | COMPOUNDS AND METHODS TARGETING HUMAN TAU | Non-Final OA | Eli Lilly and Company |
| 17499777 | METHODS FOR DETECTING TRAUMATIC BRAIN INJURY | Non-Final OA | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 17568619 | BK CHANNEL-MODULATING PEPTIDES AND THEIR USE | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17050775 | NATURAL KILLER CELLS ENGINEERED TO EXPRESS CHIMERIC ANTIGEN RECEPTORS WITH IMMUNE CHECKPOINT BLOCKADE | Final Rejection | Board of Regents, The University of Texas System |
| 17655741 | REDUCTION OF APPLICATION-RELATED SIDE REACTION OF A THERAPEUTIC ANTIBODY | Non-Final OA | Hoffmann-La Roche Inc. |
| 17317057 | DETECTION OF AUTOREACTIVE FECAL IMMUNOGLOBULIN A (IGA) FOR DIAGNOSIS OF LUPUS | Final Rejection | MUSC Foundation for Research Development |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy